Guidelines For Treatment Of Pneumonia Research Articles

Impact of Stewardship Pharmacist Driven MRSA Nasal Surveillance and De-escalation of Anti-MRSA Therapy

Background: Intravenous vancomycin is commonly used as initial empiric coverage for pneumonia but is often unnecessary. MRSA nasal surveillance cultures (MRSA nasal swab) have been highlighted in recent literature and the 2019 IDSA Pneumonia Treatment Guidelines as a tool to avoid unnecessary MRSA coverage in pneumonia. A negative MRSA nasal swab can be utilized by clinicians to de-escalate anti-MRSA therapies for pneumonia. The purpose of this study is to determine if implementing stewardship pharmacist driven MRSA nasal surveillance increases use of the test and reduces the inappropriate use of vancomycin for MRSA coverage in patients with pneumonia. Method: This study was a retrospective chart review and was approved by the Trinity Health of New England Institutional Review Board. For this initiative, a stewardship pharmacist evaluated all patients receiving vancomycin for anti-MRSA therapy at Saint Francis Hospital and Medical Center in Hartford, CT. If the patient’s indication was pneumonia and a MRSA nasal swab had not been ordered, the pharmacist contacted the patient’s provider and requested an order for it. Upon receipt of a negative MRSA nasal swab result, the pharmacist recommended discontinuation of vancomycin to the provider if appropriate. Outcomes from the first four weeks of the pharmacist-driven initiative (April 10, 2023 to May 5, 2023) were compared to the four weeks prior to the initiative (March 13, 2023 to April 7, 2023) as a control group. The primary outcome of this study was percentage of patients who received a MRSA nasal swab. Secondary outcomes included percentage of patients who had vancomycin appropriately de-escalated based on MRSA nasal swab results and mean length of vancomycin therapy. Result: 116 patients met inclusion criteria: 61 in the control group and 55 in the intervention group. Percentage of swabs ordered increased from 36.1% (22/61) without pharmacist intervention to 80.0% (44/55) with pharmacist intervention (p < 0 .0001). There were also increased rates of vancomycin de-escalation in patients with pharmacist intervention, with 58.2% (32/55) of patients in the intervention group having vancomycin discontinued following a negative MRSA swab compared to 19.7% (12/61) in the control group (p < 0 .0001). Conclusion: The results suggest implementing a pharmacist driven MRSA nasal surveillance program into practice could increase the number of MRSA nasal swabs ordered and in turn promote more timely de-escalation of vancomycin in patients with pneumonia. The results from this study can be used to support the wide-spread use of pharmacist driven MRSA nasal surveillance protocols at other institutions.

Hydrogen, a Novel Therapeutic Molecule, Regulates Oxidative Stress, Inflammation, and Apoptosis.

Molecular hydrogen (H2) is a colorless and odorless gas. Studies have shown that H2 inhalation has the therapeutic effects in many animal studies and clinical trials, and its application is recommended in the novel coronavirus pneumonia treatment guidelines in China recently. H2 has a relatively small molecular mass, which helps it quickly spread and penetrate cell membranes to exert a wide range of biological effects. It may play a role in the treatment and prevention of a variety of acute and chronic inflammatory diseases, such as acute pancreatitis, sepsis, respiratory disease, ischemia reperfusion injury diseases, autoimmunity diseases, etc.. H2 is primarily administered via inhalation, drinking H2-rich water, or injection of H2 saline. It may participate in the anti-inflammatory and antioxidant activity (mitochondrial energy metabolism), immune system regulation, and cell death (apoptosis, autophagy, and pyroptosis) through annihilating excess reactive oxygen species production and modulating nuclear transcription factor. However, the underlying mechanism of H2 has not yet been fully revealed. Owing to its safety and potential efficacy, H2 has a promising potential for clinical use against many diseases. This review will demonstrate the role of H2 in antioxidative, anti-inflammatory, and antiapoptotic effects and its underlying mechanism, particularly in coronavirus disease-2019 (COVID-19), providing strategies for the medical application of H2 for various diseases.

Association of Penicillin or Cephalosporin Allergy Documentation and Antibiotic Use in Hospitalized Patients with Pneumonia

Treatment guidelines for pneumonia recommend beta-lactam antibiotic-based therapy. Although reported penicillin allergy is common, more than 90% of patients with reported penicillin allergy are not allergic. We evaluated the association of a documented penicillin and/or cephalosporin (P/C) allergy to antibiotic use for the treatment of inpatient pneumonia. This was a national cross-sectional study conducted among Vizient, Inc., network hospitals that voluntarily contributed data. Among hospitalized patients with pneumonia, we examined the relation of a documented P/C allergy in the electronic health record to prevalence of first-line beta-lactam antibiotic administration and alternative antibiotics using multivariable log-binomial regression with generalized estimating equations. Of 2,276 inpatients receiving antibiotics for pneumonia at 95 U.S. hospitals, 450 (20%) had a documented P/C allergy. Compared with pneumonia patients without a documented P/C allergy, patients with a documented P/C allergy had reduced prevalence of first-line beta-lactam antibiotic use (adjusted prevalence ratio [aPR] 0.79; 95% confidence interval [95% CI] 0.69-0.89]). Patients with high-risk P/C reactions (n= 91) had even lower prevalence of first-line beta-lactam antibiotic use (aPR 0.47; 95% CI 0.35-0.64). Alternative antibiotics associated with a higher use in pneumonia patients with a documented P/C allergy included carbapenems (aPR 1.61; 95% CI 1.22-2.13) and fluoroquinolones (aPR 1.52; 95% CI 1.21-1.91). Inpatients with documented P/C allergy and pneumonia were less likely to receive recommended beta-lactams and more likely to receive carbapenems and fluoroquinolones. Inpatient allergy assessment may improve optimal antibiotic therapy for the 20% of inpatients with pneumonia and a documented P/C allergy.

Evaluation of the Appropriateness of Empirical Antibiotic Prescription after Implementation of Antibiotic Treatment Guidelines for Pneumonia in a Hospital

Evaluation of the Appropriateness of Empirical Antibiotic Prescription after Implementation of Antibiotic Treatment Guidelines for Pneumonia in a Hospital

Comparative effectiveness of injectable penicillin versus a combination of penicillin and gentamicin in children with pneumonia characterised by indrawing in Kenya: a retrospective observational study

ObjectivesKenyan guidelines for antibiotic treatment of pneumonia recommended treatment of pneumonia characterised by indrawing with injectable penicillin alone in inpatient settings until early 2016. At this point, they were revised...

Effect of enhanced feedback to hospitals that are part of an emerging clinical information network on uptake of revised childhood pneumonia treatment policy: study protocol for a cluster randomized trial

BackgroundThe national pneumonia treatment guidelines in Kenya changed in February 2016 but such guideline changes are often characterized by prolonged delays in affecting practice. We designed an enhanced feedback intervention, delivered within an ongoing clinical network that provides a general form of feedback, aimed at improving and sustaining uptake of the revised pneumonia treatment policy. The objective was to determine whether an enhanced feedback intervention will improve correctness of classification and treatment of childhood pneumonia, compared to an existing approach to feedback, after nationwide treatment policy change and within an existing hospital network.Methods/designA pragmatic, cluster randomized trial conducted within a clinical network of 12 Kenyan county referral hospitals providing inpatient pediatric care to children (aged 2–59 months) with acute medical conditions between March and November 2016. The intervention comprised enhanced feedback (monthly written feedback incorporating goal setting, and action planning delivered by a senior clinical coordinator for selected pneumonia indicators) and this was compared to standard feedback (2-monthly written feedback on multiple quality of pediatric care indicators) both delivered within a clinical network promoting clinical leadership linked to mentorship and peer-to-peer support, and improved use of health information on service delivery. The 12 hospitals were randomized to receive either enhanced feedback (n = 6) or standard feedback (n = 6) delivered over a 9-month period following nationwide pneumonia treatment policy change. The primary outcome is the proportion of all admitted patients with pneumonia (fulfilling criteria for treatment with orally administered amoxicillin) who are correctly classified and treated in the first 24 h. The secondary outcome will be measured over the course of the admission as any change in treatment for pneumonia after the first 24 h.DiscussionThis trial protocol employs a pragmatic trial design during a period of nationwide change in treatment guidelines to address two high-priority areas within implementation research: promoting adoption of health policies and optimizing effectiveness of feedback.Trial registrationClinicalTrials.gov, ID: NCT02817971. Registered retrospectively on 27 June 2016

Characterizing non-linear effects of hospitalisation duration on antimicrobial resistance in respiratory isolates: an analysis of a prospective nationwide surveillance system

ObjectivesOur objective was to systematically study the influence of length of hospital stay on bacterial resistance in relevant respiratory tract isolates. MethodsUsing prospective epidemiological data from the National Swiss Antibiotic Resistance Surveillance System, susceptibility testing results for respiratory isolates retrospectively retrieved from patients hospitalised between 2008 and 2014 were compiled. Generalized additive models were used to illustrate resistance rates relative to hospitalisation duration and to adjust for co-variables. ResultsIn all, 19 622 isolates of six relevant and predominant species were included. Resistance patterns for the predominant species showed a species-specific and antibiotic-resistance-specific profile in function of hospitalisation duration. The oxacillin resistance profile in Staphylococcus aureus isolates was constantly increasing (monophasic). The pattern of resistance to cefepime in Pseudomonas aeruginosa was biphasic with a decreasing resistance rate for the first 5 days of hospitalisation and an increase for days 6–30. A different biphasic pattern occurred in Escherichia coli regarding amoxicillin-clavulanic acid resistance: odds/day increased for the first 7 days of hospitalisation and then remained stable for days 8–30. In the adjusted models epidemiological characteristics such as age, ward type, hospital type and linguistic region were identified as relevant co-variables for the resistance rates. The contribution of these confounders was specific to the individual species/antibiotic resistance models. ConclusionsResistance rates do not follow a dichotomic pattern (early versus late nosocomial) as suggested by current hospital-acquired pneumonia treatment guidelines. Duration of hospitalisation rather appears to have a more complex and non-linear relationship with bacterial resistance in hospital-acquired pneumonia, also depending on host and environmental factors.

Clinico-Microbiological Profile and Drug Sensitivity Pattern among Pneumonia Patients in a Tertiary Care Hospital

Background: The true incidence of pneumonia acquired in the community is unknown, but this is a clinical problem worldwide especially in developing countries and remains a leading cause of death in India. Aim: To study the microbiological profile of patients with pneumonia and to study drug-sensitivity pattern. Methods: The present study was undertaken in department of Microbiology, NRI General Hospital, Chinakakani, Andhra Pradesh. For the study, 55 patients diagnosed with pneumonia were selected. In all studied patients-routine laboratory tests, sputum, tracheal aspirates & blood cultures were done. Results:Streptococcus pneumoniae was the commonest pathogen (18.97%), followed by Klebsiella pneumoniae (17.24%), Pseudomonas (13.79%), Staphylococcus aureus (6.9%) and other Gram-negative bacilli. Pneumonia was predominant in males (69.09%) and elderly age group (70.90%). Majority of Gram-positive organisms were susceptible to Erythromycin and Vancomycin. Most of the Gram-negative bacilli were sensitive to Imipenem, Ciprofloxacin & Gentamicin. Conclusion: Microbiological profile of pneumonia varies geographically. There is a need to conduct regular prevalence and antibiogram studies to develop empirical guidelines for treatment of pneumonia in that particular region.

Have Guidelines for Healthcare-Associated Pneumonia Improved Treatment Accuracy?

In 2005, a formal classification of “healthcare-associated pneumonia” was added to pneumonia-treatment guidelines, specifying that patients with substantial exposure to microbial flora in hospitals or other residential facilities start treatment with broad-spectrum antibiotics directed at multidrug-resistant pathogens (Am J Respir Crit Care Med 2005; 171:388). In theory, this mandate should have resulted in better matches between initial treatment and …

Antibiotic prescribing on admission to patients with pneumonia and prior outpatient antibiotic treatment: a cohort study on clinical outcome

ObjectiveMost pneumonia treatment guidelines recommend that prior outpatient antibiotic treatment should be considered when planning inpatient antibiotic regimen. Our purpose was to study in patients admitted for community-acquired pneumonia the...

Effects of adherence to ventilator-associated pneumonia treatment guidelines on clinical outcomes

Two guidelines are currently available to guide Japanese clinicians caring for patients with ventilator-associated pneumonia (VAP): the 2005 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines or the 2008 Japanese Respiratory Society (JRS) guidelines. We aimed to measure compliance with guideline recommendations for VAP in Japanese intensive care units (ICUs) and to assess the effects of guideline-compliant treatment on outcomes. We retrospectively reviewed the records of all patients with microbiologically confirmed VAP in five Japanese ICUs between January 1, 2006, and December 31, 2009. We evaluated whether empiric antibiotic prescriptions were guideline compliant and correlated compliance with clinical outcomes. Among the 95 patients with VAP who were included, 85 patients received empiric antibiotics. Of these, therapy of 62 patients (73%) was appropriate based on in vitro sensitivity testing. Using ATS/IDSA criteria, 16 patients (19%) received guideline-compliant therapy and 69 patients (81%) received noncompliant treatment. Using JRS criteria, 24 patients (28%) received guideline-compliant therapy and 61 patients (72%) received noncompliant treatment. All-cause 28-day mortality was 24%. When compared to patients who received noncompliant therapy, there were no differences in 28-day mortality rates for patients who received ATS/IDSA guideline-compliant regimens (25 vs. 25%, p=1.00) or JRS guideline-compliant regimens (21 vs. 26%, p=0.78). Our study demonstrates poor compliance with guideline-recommended antibiotic therapy for VAP in Japanese ICUs. Compliance with current VAP guidelines was not associated with increased rates of appropriate antibiotic treatment or improved 28-day mortality.

New aspirations: the debate on aspiration pneumonia treatment guidelines

Aspiration pneumonia occurs most commonly in patients with a predisposition to aspiration (eg, those with neurological bulbar dysfunction). There is limited evidence regarding the involvement of anaerobes in most cases of aspiration pneumonia. Most patients respond to treatment for aspiration pneumonia without specific anti-anaerobic therapy such as metronidazole. Metronidazole has adverse side effects, and widespread use where not indicated can promote carriage of multiresistant intestinal flora such as vancomycin-resistant enterococci. Use of metronidazole may be appropriate in patients with aspiration pneumonia and evidence of a lung abscess, necrotising pneumonia, putrid sputum or severe periodontal disease.

Empirical treatment of influenza-associated pneumonia in primary care: a descriptive study of the antimicrobial susceptibility of lower respiratory tract bacteria (England, Wales and Northern Ireland, January 2007–March 2010)

ObjectivesTo determine the susceptibility of lower respiratory tract (LRT) isolates of Streptococcus pneumoniae, Staphylococcus aureus and Haemophilus influenzae to antimicrobial agents recommended by UK guidelines for treatment of pneumonia associated...

Definition of hospital‐acquired pneumonia and characteristics of guidelines in Japan

Hospital-acquired pneumonia is defined as pneumonia that appears for the first time within 48 h of hospital admission. Special care is needed in treatment because of poor patient conditions, including the underlying disorder, immunocompetence and general status. The 2002 hospital-acquired pneumonia guidelines were reviewed, and the current revisions were made based on those findings with the aim of producing simple and practical guidelines. Differences are seen between hospital-acquired pneumonia in the USA and Japan, and hospital-acquired pneumonia treatment guidelines matched to circumstances in Japan were considered necessary.

Economic Impact of Implementing Pneumonia Treatment Guidelines for Intravenous to Oral Conversion

Background Inpatient treatment of pneumonia produces significant costs to the health care system. In an effort to improve quality of care, decrease length of stay, and decrease drug costs associated with treating pneumonia, on October 1, 2006, the Veterans Affairs New York Harbor Healthcare System (VANYHHS) implemented guidelines for treating hospitalized patients with pneumonia. These guidelines included specific criteria for initial selection of an antimicrobial agent based on patient risk factors, conversion from intravenous (IV) to oral antibiotics, and selection of an appropriate oral agent for conversion. The primary objective of this study was assessment of the economic impact of implementing pneumonia treatment guidelines at the VANYHHS. Methods Retrospective analysis of 100 patients admitted to the VANYHHS for treatment of pneumonia was completed before implementation of the guidelines, and then those data were compared with similar data from a group of 100 patients admitted to the hospital for treatment of pneumonia after implementation of the guidelines. Electronic medical records were reviewed for (1) initial antibiotic therapy administered, (2) time needed for conversion from IV to oral antibiotics after becoming eligible for the switch based on implemented guidelines, and (3) length of hospital stay. Results Data from the preguideline group demonstrated that it took an additional 2.31 days to convert patients from IV to oral antibiotics after they were eligible for the switch to oral therapy. The mean length of stay was 9.2 days. Data from the postguideline group illustrated that the time needed to convert patients from IV to oral therapy was decreased to 1.09 days ( P = 0.002) and the mean length of stay was decreased to 8.76 days ( P = 0.677) when compared with the preguideline group data. The estimated annual cost savings from implementing pneumonia treatment guidelines based on the decrease in mean length of stay was $290,482.20 annually. Conclusion Implementing pneumonia treatment guidelines was associated with decreased length of stay and, thus, a decrease in the costs associated with treating pneumonia in an institutional setting. It is estimated that the VANYHHS could save nearly $300,000 annually as a result of the implementation of the treatment guidelines for pneumonia.

Fatal Community-Associated Methicillin-Resistant Staphylococcus aureus Pneumonia in an Immunocompetent Young Adult

Severe pneumonia caused by community-associated methicillin-resistant Staphylococcus aureus (MRSA) was reported in children soon after this pathogen emerged in the United States in the 1990s. Genes for Panton Valentine leukocidin, which are present in the majority of community-associated MRSA, are thought to enhance the ability of S aureus to cause necrotizing pneumonia. Despite the rapid spread throughout the United States of community-associated MRSA and related skin and soft-tissue infections, reports of severe pneumonia in adults have been rare. We describe a case of a healthy young adult who initially was treated as an outpatient with levofloxacin for what appeared to be typical community-acquired pneumonia. He soon returned to the emergency department (ED) with rapidly fatal necrotizing pneumonia, associated with hemoptysis, leukopenia, and sepsis syndrome, that was caused by community-associated MRSA carrying genes for Panton Valentine leukocidin. This case highlights the typical features of this form of pneumonia and the need to consider MRSA when evaluating and treating severe pneumonia in the ED. It also raises the question of whether the incidence of this form of pneumonia might be increasing in communities with a high prevalence of community-associated MRSA and whether current pneumonia treatment guidelines should be modified.

Community-acquired pneumonia in casualty: etiology, clinical features, diagnosis, and management (or a look at the "new" in pneumonia since 2002).

Community-acquired pneumonia, because of its substantial treatment costs, incidence, and mortality, is an aggressively researched diagnosis. In this review, we highlight new developments in the diagnosis, etiology, pathophysiology, treatment, and prevention of community-acquired pneumonia published since April 2002. The combined end points of improved patient care and conservation of health care resources have prompted several studies examining current professional society community-acquired pneumonia guidelines. In general, patients treated with the recommended third-generation cephalosporin and macrolide or an antipneumococcal fluoroquinolone when indicated have fared better, including reduced overall costs, inpatient days, and mortality, than those receiving alternative treatments. Etiologic identification efforts by traditional methods, blood and sputum cultures, are being questioned owing to poor success rates and, even when positive, are being underused or ignored in antibiotic selection and patient management. Newer diagnostic tests are becoming commercially available, along with tests for biologic markers that have been only recently identified as contributors to, or prognosticators of, community-acquired pneumonia. Because antibiotic resistance remains a major obstacle to successful patient treatment, prevention or mitigation of community-acquired pneumonia is gaining increasing popularity through more aggressive pneumococcal and influenza vaccination of at risk groups, even before hospital discharge from a community-acquired pneumonia admission. Although prevention is our best defense, current community-acquired pneumonia treatment guidelines are effective for treatment and cost containment. However, they should be scrutinized in light of clinical utilization data now entering the literature regarding their testing recommendations. Providers should consider encouraging focused culturing of sicker patients and those with significant comorbidities.

Comparative impact of guidelines, clinical data, and decision support on prescribing decisions: an interactive web experiment with simulated cases

ObjectiveThe aim of this study was to compare the clinical impact of computerized decision support with and without electronic access to clinical guidelines and laboratory data on antibiotic prescribing decisions. DesignA crossover trial was conducted of four levels of computerized decision support—no support, antibiotic guidelines, laboratory reports, and laboratory reports plus a decision support system (DSS), randomly allocated to eight simulated clinical cases accessed by the Web. MeasurementsRate of intervention adoption was measured by frequency of accessing information support, cost of use was measured by time taken to complete each case, and effectiveness of decision was measured by correctness of and self-reported confidence in individual prescribing decisions. Clinical impact score was measured by adoption rate and decision effectiveness. ResultsThirty-one intensive care and infectious disease specialist physicians (ICPs and IDPs) participated in the study. Ventilator-associated pneumonia treatment guidelines were used in 24 (39%) of the 62 case scenarios for which they were available, microbiology reports in 36 (58%), and the DSS in 37 (60%). The use of all forms of information support did not affect clinicians' confidence in their decisions. Their use of the DSS plus microbiology report improved the agreement of decisions with those of an expert panel from 65% to 97% (p=0.0002), or to 67% (p=0.002) when antibiotic guidelines only were accessed. Significantly fewer IDPs than ICPs accessed information support in making treatment decisions. On average, it took 245 seconds to make a decision using the DSS compared with 113 seconds for unaided prescribing (p<0.001). The DSS plus microbiology reports had the highest clinical impact score (0.58), greater than that of electronic guidelines (0.26) and electronic laboratory reports (0.45). ConclusionWhen used, computer-based decision support significantly improved decision quality. In measuring the impact of decision support systems, both their effectiveness in improving decisions and their likely rate of adoption in the clinical environment need to be considered. Clinicians chose to use antibiotic guidelines for one third and microbiology reports or the DSS for about two thirds of cases when they were available to assist their prescribing decisions.

Community‐Acquired Pneumonia in the Elderly

Pneumonia in the elderly is a common and serious problem with a clinical presentation that can differ from that in younger patients. Older patients with pneumonia complain of significantly fewer symptoms than do younger patients, and delirium commonly occurs. Indeed, delirium may be the only manifestation of pneumonia in this group of patients. Alcoholism, asthma, immunosuppression, and age >70 years are risk factors for community-acquired pneumonia in the elderly. Among nursing home residents, the following are risk factors for pneumonia: advanced age, male sex, difficulty in swallowing, inability to take oral medications, profound disability, bedridden state, and urinary incontinence. Streptococcus pneumoniae is the most common cause of pneumonia among the elderly. Aspiration pneumonia is underdiagnosed in this group of patients, and tuberculosis always should be considered. In this population an etiologic diagnosis is rarely available when antimicrobial therapy must be instituted. Use of the guidelines for treatment of pneumonia issued by the Infectious Diseases Society of America, with modification for treatment in the nursing home setting, is recommended.

Impact of pneumonia treatment guidelines on outcomes and costs

Impact of pneumonia treatment guidelines on outcomes and costs